Initiation by Merck of a Phase 2 trial in Alzheimer's disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights ...

Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable ...

Merck & Co has a lower P/E than the aggregate P/E of 26.97 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to ...

Merck is holding strong among billionaire favorites, despite the broader healthcare sector dodging investor affection like a ...

Goldman Sachs analyst Asad Haider assumed coverage of Merck (MRK) with a Buy rating and price target of $103, down from $129. Following the ...

Merck Sharp & Dohme Federal Credit Union marked its 75th Anniversary with a memorable Annual Meeting held at Pine Crest ...

Learn more about whether Corcept Therapeutics Incorporated or Merck & Co., Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

both companies will deliver essential solutions for reliable data access across value chains. This integration builds trust ...

A company can account for changes in the market value of its various fixed assets by conducting a revaluation of the fixed assets. Revaluation of a fixed asset is the accounting process of ...